Laser Therapy

Erchonia® EVRL™ for Peripheral Neuropathy

N/A

Recruiting

Research Sponsored by Erchonia Corporation

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Constant feet pain on-going over at least the past 3 months.

Agrees to refrain from taking a dosage of analgesic (pain medication) for at least 6 hours before a scheduled VAS foot pain rating is to be recorded.

Must not have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Upbaseline and 3 weeks

Awards & highlights

Study Summary

This trial will test whether the Erchonia EVRL machine can provide relief from foot pain caused by diabetic neuropathy.

Eligible Conditions

Peripheral Neuropathy
Diabetic Neuropathy

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

Select...

You have been experiencing consistent foot pain for at least 3 months.

Select...

You can't take any pain medication for at least 6 hours before we measure your foot pain.

Select...

You have foot pain that scores 50 or higher on a 0-100 pain scale.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 3 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 3 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants With a 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS)

Secondary outcome measures

Neuropathic Pain Symptom Inventory (NPSI)

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Erchonia® EVRL™Active Control1 Intervention

The Erchonia® EVRL™ is made up of (1) 635 nanometers red laser diode and (1) 405 nanometers violet laser diode mounted in a portable handheld device.

Group II: Placebo LaserPlacebo Group1 Intervention

The Placebo Laser has the same appearance as the Erchonia® EVRL™ but does not emit any therapeutic light.

0 / 3Eligibility criteria met

Find a site

Who is running the clinical trial?

Erchonia CorporationLead Sponsor

43 Previous Clinical Trials

1,935 Total Patients Enrolled

Media Library

Erchonia® EVRL™ (Laser Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05291975 — N/A

Peripheral Neuropathy Research Study Groups: Erchonia® EVRL™, Placebo Laser

Peripheral Neuropathy Clinical Trial 2023: Erchonia® EVRL™ Highlights & Side Effects. Trial Name: NCT05291975 — N/A

Erchonia® EVRL™ (Laser Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05291975 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the maximum capacity of participants for this trial?

"Affirmative. Clinicaltrials.gov attests that this research, which was initially proposed on February 17th 2022, is actively looking for participants. A total of 64 individuals must be recruited from 3 distinct medical sites."

Answered by AI

Does enrollment in this project remain open to interested participants?

"Indeed, the clinical trial is looking for new participants. Initially posted on February 17th 2022 and freshly updated on August 1st 2022, 64 volunteers are needed from 3 medical centers to take part in this study."

Answered by AI